Hans Schreiber

Hans Schreiber is a Professor in the Department of Pathology at the University of Chicago, within the Pritzker School of Medicine. His research focuses on understanding the interplay between cancer cells and the immune system, particularly exploring how cancer-specific mutations and antigens can be targeted for therapeutic intervention. He investigates mechanisms of immune evasion by tumors and develops strategies to enhance immunotherapeutic approaches.

Education:

• MD, University of Freiburg, Germany (1969)
• D.M.Sc. in Experimental Pathology/Radiation Biology, University of Freiburg (1969)
• Postdoctoral Fellowship, Oak Ridge National Laboratory (1970–1973)
• Ph.D., University of Chicago (1977)
• Residency in Anatomic Pathology, University of Chicago

Research Interests: His lab combines immunology, genetics, and biochemistry to identify cancer-specific targets, such as neoantigens and mutations, to design novel therapies. Key areas include T-cell receptor engineering, CAR-T cell therapy, and understanding tumor-stroma interactions. He emphasizes translating preclinical findings into clinically relevant strategies for cancer treatment.

Grants & Funding:

• Principal Investigator on multiple NIH grants (e.g., P01CA097296, R01CA037156) focusing on tumor immunology and immunotherapeutic development.
• Co-Investigator on interdisciplinary training programs (e.g., T32AI007090).

Labs & Collaborations: His laboratory collaborates widely, exploring topics like adoptive T-cell therapy, immune checkpoint inhibitors, and engineered CAR-T cells. Key projects involve studying tumor microenvironment dynamics and developing tools for precise antigen targeting.